JACOBSON PHARMA CORPORATION LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6 HKD | 0.00% |
|
+1.69% | -6.25% |
| Feb. 27 | Jacobson Pharma Raises HK$39 Million from Share Placement | MT |
| 2023 | Jacobson Pharma Corporation Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.6B 204M | Sales 2023 | 1.79B 229M | Capitalization | 1.85B 236M |
|---|---|---|---|---|---|
| Net income 2022 | 178M 22.79M | Net income 2023 | 251M 32.13M | EV / Sales 2022 | 1.33 x |
| Net Debt 2022 | 880M 113M | Net Debt 2023 | 511M 65.36M | EV / Sales 2023 | 1.32 x |
| P/E ratio 2022 |
7.01
x | P/E ratio 2023 |
7.39
x | Employees | 1,588 |
| Yield 2022 |
5.97% | Yield 2023 |
5.34% | Free-Float | 20.34% |
More Fundamentals
* Assessed data
More news
| 1 week | +1.69% | ||
| Current month | +5.26% | ||
| 1 month | +5.26% | ||
| 3 months | +1.69% | ||
| 6 months | -4.76% | ||
| Current year | -6.25% |
1 week
0.58
0.60
1 month
0.550.60
Current year
0.540.64
1 year
0.541.08
3 years
0.441.11
5 years
0.441.87
10 years
0.442.28
| Managers | Title | Age | Since |
|---|---|---|---|
Kwong Yip Sum
CEO | Chief Executive Officer | 61 | 16-02-15 |
Chun Kau Yu
DFI | Director of Finance/CFO | 52 | 18-12-31 |
Yue Wai Pun
BRD | Director/Board Member | 72 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chun Leung Yim
BRD | Director/Board Member | 62 | 16-03-31 |
Sing Kwong Lam
BRD | Director/Board Member | 65 | 16-04-10 |
Chun Man Young
BRD | Director/Board Member | 60 | 16-08-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 0.6 | 0.00% | 334 000 |
| 24-05-13 | 0.6 | 0.00% | 1,108,000 |
| 24-05-10 | 0.6 | +1.69% | 460,000 |
| 24-05-09 | 0.59 | 0.00% | 642,000 |
| 24-05-08 | 0.59 | 0.00% | 634,000 |
Delayed Quote Hong Kong S.E., May 14, 2024 at 04:08 am EDT
More quotes
Jacobson Pharma Corporation Ltd is an investment holding company principally engaged in the manufacturing and sale of generic drugs. The Company operates its business through two segments. The Generic Drugs segment is engaged in the development, manufacture and distribution of a host of off-patent medicines for various therapeutic use. The Branded Healthcare segment is engaged in the development, manufactures and distributes branded medicines, proprietary Chinese medicines and health and wellness products. Currently the activities of two segments in this regard are primarily carried out in Hong Kong.
Sector
Pharmaceuticals
Calendar
2024-06-24
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.25% | 154M | |
| +22.10% | 43.81B | |
| +25.56% | 23.01B | |
| +19.07% | 15.27B | |
| +10.03% | 13.68B | |
| +42.96% | 11.96B | |
| -7.49% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.26% | 5.59B |
- Stock Market
- Equities
- 2633 Stock
